Solution structure of iron(III)-anthracycline complexes

被引:26
作者
Fiallo, MML
Drechsel, H
Garnier-Suillerot, A
Matzanke, BF
Kozlowski, H
机构
[1] Univ Paris 13, LPBC, ESA 7033, F-93017 Bobigny, France
[2] Univ Lubeck, Isotope Lab Nat Sci, D-2400 Lubeck, Germany
[3] Univ Wroclaw, Fac Chem, PL-50138 Wroclaw, Poland
关键词
D O I
10.1021/jm981057n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interaction of Fe3+ with the anthracycline anticancer drug idarubicin (Ida) was studied by absorption, CD, Mossbauer, and EPR spectroscopy. The formation of two major Fe3+-Ida complexes, labeled I and II, was observed. In complex I, Fe3+ ion was bound to anthracycline at the {C(12)=O; C(11)-O-} coordination site. In complex II, two Fe3+ ions were bound at sites {C(5)=O; C(6)-O-} and {C(12)=O; C(11)-O-}, respectively. Complex I was an equimolar monomeric species with a 1:1 Fe3+:Ida stoichiometry (beta(1) = 4.8 x 10(11) M-1), whereas in complex II the anthracycline ligand was bridging two metal ions, alternatively bound to both anthracycline ring chelating sites with the assumption that the ratio of Fe3+:Ida in complex II was 2:1 (beta(2) = 5.3 x 10(24) M-2). Alternatively, complex II may be oligomeric with Fe3+:Ida = 1:1 and with each Fe3+ bridging two Ida molecules. Our findings could be important in understanding the biological effects of the anthracycline-ferric complexes. Thus, providing information about the nature of the Fe3+-Ida system, we suggest that the formal 1:3 Fe3+:anthrracycline complexes, reported in the previous literature, could be a mixture of species I, II, and free ligand.
引用
收藏
页码:2844 / 2851
页数:8
相关论文
共 43 条
[1]  
AISEN P, 1978, J BIOL CHEM, V253, P1930
[2]  
[Anonymous], 1964, STABILITY CONSTANTS
[3]  
Arcamone F., 1988, ANTHRACYCLINE ANTHRA, P1
[4]  
BACHUR NR, 1984, CANCER CHEMOTH PHARM, V12, P5
[5]   STRUCTURE ELUCIDATION AND CHARACTERIZATION OF DAUNORUBICIN DEGRADATION PRODUCTS [J].
BEIJNEN, JH ;
POTMAN, RP ;
VANOOIJEN, RD ;
DRIEBERGEN, RJ ;
VOSKUILEN, MCH ;
RENEMA, J ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 34 (03) :247-257
[6]   ASPECTS OF THE DEGRADATION KINETICS OF DOXORUBICIN IN AQUEOUS-SOLUTION [J].
BEIJNEN, JH ;
VANDERHOUWEN, OAGJ ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 32 (2-3) :123-131
[7]   IRON(III) ADRIAMYCIN AND IRON(III) DAUNORUBICIN COMPLEXES - PHYSICOCHEMICAL CHARACTERISTICS, INTERACTION WITH DNA, AND ANTITUMOR-ACTIVITY [J].
BERALDO, H ;
GARNIERSUILLEROT, A ;
TOSI, L ;
LAVELLE, F .
BIOCHEMISTRY, 1985, 24 (02) :284-289
[8]   The interactions of Fe3+ ions with adriamycin studied by Fe-57 Mossbauer and electronic spectroscopies [J].
Capolongo, F ;
Giomini, M ;
Giuliani, AM ;
Matzanke, BF ;
Russo, U ;
Silvestri, A ;
Trautwein, AX ;
Barbieri, R .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1997, 65 (02) :115-122
[9]   EPR AND MAGNETIC CIRCULAR-DICHROISM SPECTROSCOPIC CHARACTERIZATION OF BACTERIOFERRITIN FROM PSEUDOMONAS-AERUGINOSA AND AZOTOBACTER-VINELANDII [J].
CHEESMAN, MR ;
KADIR, FHA ;
ALBASSEET, J ;
ALMASSAD, F ;
FARRAR, J ;
GREENWOOD, C ;
THOMSON, AJ ;
MOORE, GR .
BIOCHEMICAL JOURNAL, 1992, 286 :361-367
[10]   INDUCTION OF STABLE TRANSCRIPTIONAL BLOCKAGE SITES BY ADRIAMYCIN - GPC SPECIFICITY OF APPARENT ADRIAMYCIN DNA ADDUCTS AND DEPENDENCE ON IRON(III) IONS [J].
CULLINANE, C ;
PHILLIPS, DR .
BIOCHEMISTRY, 1990, 29 (23) :5638-5646